Dr. Dario Marchetti
Dario Marchetti, Ph.D., tumor and molecular biologist, is a tenured and endowed “Jack L. Titus” Professor of the Department of Pathology & Immunology with a joint appointment in the Department of Molecular & Cellular Biology at Baylor College of Medicine. He also acts as Director of the Circulating Tumor Cell (CTC) Core facility at Baylor College of Medicine.
Dr. Marchetti is an international recognized expert and authority in the field of CTCs as clinically useful tools to combat cancer metastasis for improved patient outcome. With keen insights into the biology of brain metastasis, he pioneered models for discoveries of molecular determinants underlying brain metastasis and biomarker properties of brain-homing CTCs.
As a consummate scientist, Dr. Marchetti’s bibliography include 179 publications of which 79 are in peer-reviewed journals in the fields of neuroscience and oncology. He has received numerous awards and secured uninterrupted funding for 25 years by receiving grants from federal, state, institutional and private Agencies.
Dr. Masashi Emoto
He is serving as a professor at Gunma University Graduate School of Health Sciences in Japan. He got the professorship in 1993 and his main research theme is NKT cells and intestinal intraepithelial T lymhocytes. Before coming back to Japan, he has worked at Max Planck Institute for Infection Biology in Berlin, Germany as a higher ranking senior scientist for approx. 10 years with Prof. Dr. Stefan H. E. Kaufman, who was a president of International Union of Immunological societies, and published many articles in prestigious journals with high impact factor. He has concentrated on identification of new natural ligand(s) for invariant NKT cells and nowadays he has succeeded to determine their chemical structures. In addition, he has recently found new T cell populations in the gut. He is a leading scientist in the field of NKT cells and intestinal intraepithelial T lymphocytes.
Dario Marchetti
Dario Marchetti, Ph.D., tumor and molecular biologist, is a tenured and endowed “Jack L. Titus” Professor of the Department
of Pathology & Immunology with a joint appointment in the Department of Molecular & Cellular Biology at Baylor College of Medicine. He also actsas Director of the Circulating Tumor Cell (CTC) Core facility
at Baylor College of Medicine. On October 1, Dr. Marchetti will be the Director of the Biomarker Research Program at Methodist Hospital Research Institute and Professor of Pathology and Genomics Medicine at
Methodist Hospital in Houston.
Dr. Marchetti is an international recognized expert and authority in the field of CTCs as clinically useful tools to combat cancer metastasis for improved patient outcome. With keen insights into the biology of
brain metastasis, he pioneered models for discoveries of molecular determinants underlying brain metastasis and biomarker properties of brain-homing CTCs.
As a consummate scientist, Dr. Marchetti’s bibliography include 179 publications of which 79 are in peer-reviewed journals in the fields of neuroscience and oncology. He has received numerous awards and secured
uninterrupted funding for 25 years by receiving grants from federal, state, institutional and private Agencies. He is a reviewer for the most prominent journals in cancer research and sits on editorial
boards of “Cancer Microenvironment, “Tumor Viruses”, “Vascular Cell”, "Clinical & Experimental Pathology", "International Journal of Oncology", “Cancer Letters”,
“Journal of Cellular Biochemistry”, “Discovery/Discovery Reports” (a journal from Harvard Medical School) and "Cancer Metastasis Reviews" among others. Dr. Marchetti is Editor-in-Chief
of the “Journal of Gene Therapy” and “Journal of Circulating Biomarkers”, and acts as Guest Editor of the International Journal of Molecular Sciences (Basel, Switzerland) on brain metastasis.
Further, heserved/serves on grant reviewing panels of the National Institutes of Health of USA and Italy, the Department of Defense of the United States, and is frequently invited as grant reviewer and consultant
for multiple national and international Agencies and Companies devoted to oncology research.
Dr. Marchetti graduated from the University of Pavia, Italy in 1979. He worked as postdoctoral fellow at the University of Illinois, Chicago (1980-1982), University of Texas Medical Branch – Galveston (Texas)
(1984-1986). He then became a research scientist at the University of Texas Health Science Center-Houston (1986-1991), Research Associate and later Instructor at UT MD Anderson Cancer Center (1992-1999), Assistant
Professor at UT-Houston (1999-2001), and Associate Professor and later Professor (with tenure) at LSU-Baton Rouge, Louisiana (2002-2007) prior to joining the faculty at Baylor College of Medicine and Methodist
Hospital on October 1, 2015.
Masashi Emoto
He is serving as a professor at Gunma University Graduate School of Health Sciences in Japan. He got the professorship in 1993 and his
main research theme is NKT cells and intestinal intraepithelial T lymhocytes. Before coming back to Japan, he has worked at Max Planck Institute for Infection Biology in Berlin, Germany as a higher ranking senior
scientist for approx. 10 years with Prof. Dr. Stefan H. E. Kaufman, who was a president of International Union of Immunological societies, and published many articles in prestigious journals with high impact
factor. He has concentrated on identification of new natural ligand(s) for invariant NKT cells and nowadays he has succeeded to determine their chemical structures. In addition, he has recently found new T cell
populations in the gut. He is a leading scientist in the field of NKT cells and intestinal intraepithelial T lymphocytes.
Submit Manuscript
General Internal Medicine and Clinical Innovations (GIMCI), is now open for submissions. You can submit your manuscript to: editor.gimci@oatext.com alternatively
to: editor.gimci@oatextjournals.com
External Databases & Indexes
- CAS
- Google scholar
- Crossref
- Refseek
- ROAD directory
- WorldCat
- PubMed*
* Only selected articles are indexed in PubMed.
All published articles are provided with DOI and are permanently archived at Open Access Text website in PDF and HTML formats.
Publication Charges
General Internal Medicine and Clinical Innovations is an Open Access journal and we do not charge the end user when accessing a manuscript or any article. This allows the scientific community to
view, download, distribution of an article in any medium, provided that the original work is properly cited, under the term of "Creative Commons Attribution License". In line with other open access
journals we provide a flat fee submission structure on the acceptance of a peer-reviewed article which covers in part the entirety of the publication pathway (the article processing charge). The process includes
our maintenance, submission and peer review systems and international editing, publication and submission to global indexing and tracking organisations and archiving to allow instant access to the whole article
and associated supplementary documents. We also have to ensure enough investment to secure a sustainable model which ethically, legally and financially stable.
The publication charges for General Internal Medicine and Clinical Innovations are 1500 GBP.
Frequently Asked Questions (FAQs)
Why are your charges set at these levels?
All articles published in OA Text are open access. Open Access publishing implies that all readers, anywhere in the world, are allowed unrestricted to full text of articles, immediately on publication in OA Text
Journals. The Article Publication Charges pay for the editorial and production costs of the journal, for hosting the website, publishing articles online, preparing HTML , PDF and XML versions of the articles
and submitting the articles in electronic citation database like CrossRef.
Our financial goals are to:
- Recover capitalization costs;
- Produce sufficient revenue to allow for a sustainable and scalable publishing program, under continuous development;
- Bend the publication-charge cost downward over time.
Who will pay the APC?
Corresponding author or Co-authors has to make the payment on acceptance of the article.
When should I pay?
Corresponding author or the paying institutions should arrange for the payment once they are notified regarding acceptance of the article. APC is exempted for cases in which a wavier agreement has been made in-prior
to submission.
*We request an immediate attention towards the payment as the articles will not be published unless the charges have been paid.
How do I pay?
Authors or institutions can make payments by two modes as per their convenience.
- Wire/Bank transfer
- Card payment
Note: No taxes are included in this charge, taxes will be applicable as per the policies of the country of the payee. Additional transaction charges may be levied on the author.
Can I be eligible for wavier on APC?
The waiver request will be considered on a case-by-case basis, and will be provided accordingly.
*The Waiver requests must be made during the submission process and will not be accepted after processing of the manuscript.
Do I have to pay if my manuscript is rejected?
No, Article processing charges will not be applicable for articles rejected by the Editorial office.
Withdrawal Charges
Are reprints of my article included in the article processing charges (APCs)?
No, Article processing charges (APCs) do not include the charges for the reprints. Reprints facility is optional and should be order separately.
Special Issue
Trends in Stem Cell Treatments
Editor Affiliation:
Ahmed Malki
Director of Biomedical Science Program
Qatar University
Qatar
Submission date: October 30, 2018
Publication date: November 26, 2018
Description of the Special Issue: There has been a great deal of interest in recent years in the use of stem cells in the treatment of a broad spectrum of diseases and many predictions have been made which
suggest that the future practice of medicine will rely heavily on applications in stem cell technology. There has been steady progress in understanding the biological nature of stem cells, their isolation and
expansion, and how they make fate decisions.
Submit manuscript to editor.gimci@oatext.com
Pregnancy Complications
Editor Affiliation:
Elizabeth Puscheck
Hutzel Women’s Hospital
USA
Submission date: October 30, 2018
Publication date: November 26, 2018
Description of the Special Issue: The special issue on Pregnancy complications welcomes manuscripts on all the circumstantial topics related to stages of pregnancy and child health process encompassing clinical,
physical, physiological, emotional, social and multicultural aspects and complications during pregnancy and creates a platform for the authors to make their contribution towards the journal.
Submit manuscript to editor.gimci@oatext.com
